Citation:Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE 2012

Citation

Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur Urol 2012 May;61(5):865-74 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22104593.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE 2012	For asymptomatic men without a prostate cancer diagnosis, what is the recommended PSA testing strategy with respect to age at first PSA test, subsequent testing intervals and cut-off levels?	Dr. med. univ. Dana Stefanovic	completed
Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE 2012 2	For asymptomatic men without a prostate cancer diagnosis, what is the recommended PSA testing strategy with respect to age at first PSA test, subsequent testing intervals and cut-off levels?	Cindy Peng	completed
Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE 2012 3	For asymptomatic men without a prostate cancer diagnosis, what is the recommended PSA testing strategy with respect to age at first PSA test, subsequent testing intervals and cut-off levels?	Tracy Tsang	completed

Compare quality appraisals for each clinical question

• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what is the recommended PSA testing strategy with respect to age at first PSA test, subsequent testing intervals and cut-off levels?|]] (compare critical appraisals)
• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what is the recommended PSA testing strategy with respect to age at first PSA test, subsequent testing intervals and cut-off levels?|]] (compare critical appraisals)
• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what is the recommended PSA testing strategy with respect to age at first PSA test, subsequent testing intervals and cut-off levels?|]] (compare critical appraisals)

Cited by

1. PSA Testing strategies
2. Table 2.4. Estimates of increments in absolute percentage cumulative risk of prostate cancer death above the risk at a baseline PSA of < 1 ng/mL (Orsted et al, 2012) or the lowest quarter of the PSA distribution (Vickers et al 2013) by age, length of follow-up and baseline PSA level
3. Table 2.4. Estimates of increments in absolute percentage cumulative risk of prostate cancer death above the risk at a baseline PSA of < 1 ng/mL (Orsted et al, 2012) or the lowest quarter of the PSA distribution (Vickers et al 2013) by age, length of follow-up and baseline PSA level